Trials / Not Yet Recruiting
Not Yet RecruitingNCT07078955
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
A Phase 2, Multicenter, Randomized, Open-Labeled, Artificial Tear-Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (estimated)
- Sponsor
- BRIM Biotechnology Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BRM421 Ophthalmic Solution, 0.03% | A topical drop of 0.03% BRM421 ophthalmic solution. |
| DRUG | Artificial Tear | A topical drop of Artificial Tear. |
| DRUG | BRM421 Ophthalmic Solution, 0.06% | A topical drop of 0.06% BRM421 ophthalmic solution. |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-11-01
- Completion
- 2027-03-01
- First posted
- 2025-07-22
- Last updated
- 2025-10-20
Locations
1 site across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07078955. Inclusion in this directory is not an endorsement.